{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:54:56Z","timestamp":1781812496447,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12928-026-01255-5","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:23:21Z","timestamp":1772551401000},"page":"660-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-0226","authenticated-orcid":false,"given":"Sho","family":"Nakao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Higashino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"1255_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.5603\/KP.2017.0216","volume":"75","author":"V Aboyans","year":"2017","unstructured":"Aboyans V, Ricco JB, Bartelink ML, Bj\u00f6rck M, Brodmann M, Cohner T, et al. ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Kardiol Pol (Polish Heart. Journal). 2017;75:1065\u2013160. https:\/\/doi.org\/10.5603\/KP.2017.0216.","journal-title":"Journal)"},{"key":"1255_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jcin.2016.01.007","volume":"9","author":"O Iida","year":"2016","unstructured":"Iida O, Takahara M, Soga Y, Hirano K, Yamauchi Y, Zen K, et al. The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions. JACC Cardiovasc Interv. 2016;9:828\u201334. https:\/\/doi.org\/10.1016\/j.jcin.2016.01.007.","journal-title":"JACC Cardiovasc Interv"},{"key":"1255_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcin.2022.01.019","volume":"15","author":"O Iida","year":"2022","unstructured":"Iida O, Takahara M, Soga Y, Yamaoka T, Fujihara M, Kawasaki D, et al. 1-year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration. JACC Cardiovasc Interv. 2022;15:630\u20138. https:\/\/doi.org\/10.1016\/j.jcin.2022.01.019.","journal-title":"JACC Cardiovasc Interv"},{"key":"1255_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2011.09.036","volume":"59","author":"A Tosaka","year":"2012","unstructured":"Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.036.","journal-title":"J Am Coll Cardiol"},{"key":"1255_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jcin.2021.03.030","volume":"14","author":"S Ichihashi","year":"2021","unstructured":"Ichihashi S, Takahara M, Iida O, Suzuki K, Yamaoka T, Maeda K, et al. Clinical impact of stent graft thrombosis in femoropopliteal arterial lesions. JACC Cardiovasc Interv. 2021;14:1137\u201347. https:\/\/doi.org\/10.1016\/j.jcin.2021.03.030.","journal-title":"JACC Cardiovasc Interv"},{"key":"1255_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1177\/15385744241253170","volume":"58","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Takahara M, Tobita K, Hayakawa N, Mori S, Iwata Y, et al. Contemporary therapy of femoropopliteal in-stent restenosis \/ occlusion, 36-month follow up study. Vasc Endovasc Surg. 2024;58:693\u2013700. https:\/\/doi.org\/10.1177\/15385744241253170.","journal-title":"Vasc Endovasc Surg"},{"key":"1255_CR7","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40:2632\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehz372.","journal-title":"Eur Heart J"},{"key":"1255_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2021.05.003","volume":"78","author":"RM Bauersachs","year":"2021","unstructured":"Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, et al. Total ischemic event reduction with Rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial. J Am Coll Cardiol. 2021;78:317\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2021.05.003.","journal-title":"J Am Coll Cardiol"},{"key":"1255_CR9","doi-asserted-by":"publisher","first-page":"E212","DOI":"10.1002\/ccd.25387","volume":"83","author":"KJ Rocha-Singh","year":"2014","unstructured":"Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212\u201320. https:\/\/doi.org\/10.1002\/ccd.25387.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1255_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jvir.2009.05.031","volume":"20","author":"D Siablis","year":"2009","unstructured":"Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20:1141\u201350. https:\/\/doi.org\/10.1016\/j.jvir.2009.05.031.","journal-title":"J Vasc Interv Radiol"},{"key":"1255_CR11","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449.","journal-title":"Circulation"},{"key":"1255_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost"},{"key":"1255_CR13","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jvs.2009.09.044","volume":"50","author":"MS Conte","year":"2009","unstructured":"Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009;50:1462\u2013e731. https:\/\/doi.org\/10.1016\/j.jvs.2009.09.044.","journal-title":"J Vasc Surg"},{"key":"1255_CR14","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa2000052.","journal-title":"N Engl J Med"},{"key":"1255_CR15","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","volume":"42","author":"V Aboyans","year":"2021","unstructured":"Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42:4013\u201324. https:\/\/doi.org\/10.1093\/eurheartj\/ehab390.","journal-title":"Eur Heart J"},{"key":"1255_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jvs.2023.04.026","volume":"78","author":"S Bhuta","year":"2023","unstructured":"Bhuta S, Ariss RW, Ding L, Nazir S, Magee GA, Garg PK, et al. Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention. J Vasc Surg. 2023;78:498\u2013e5051. https:\/\/doi.org\/10.1016\/j.jvs.2023.04.026.","journal-title":"J Vasc Surg"},{"key":"1255_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jvs.2013.10.050","volume":"59","author":"T Dohi","year":"2014","unstructured":"Dohi T, Iida O, Soga Y, Hirano K, Suzuki K, Takahara M, et al. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions. J Vasc Surg. 2014;59:1009\u2013e10151. https:\/\/doi.org\/10.1016\/j.jvs.2013.10.050.","journal-title":"J Vasc Surg"},{"key":"1255_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12928-016-0411-3","volume":"32","author":"T Ishihara","year":"2017","unstructured":"Ishihara T, Iida O, Okamoto S, Fujita M, Masuda M, Nanto K, et al. Potential mechanisms of in-stent occlusion in the femoropopliteal artery: an angioscopic assessment. Cardiovasc Interv Ther. 2017;32:313\u20137. https:\/\/doi.org\/10.1007\/s12928-016-0411-3.","journal-title":"Cardiovasc Interv Ther"},{"key":"1255_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jcin.2016.11.005","volume":"10","author":"H Mori","year":"2017","unstructured":"Mori H, Lutter C, Yahagi K, Harari E, Kutys R, Fowler DR, et al. Pathology of chronic total occlusion in bare-metal versus drug-eluting stents: implications for revascularization. JACC Cardiovasc Interv. 2017;10:367\u201378. https:\/\/doi.org\/10.1016\/j.jcin.2016.11.005.","journal-title":"JACC Cardiovasc Interv"},{"key":"1255_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jvs.2008.04.013","volume":"48","author":"MG Davies","year":"2008","unstructured":"Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. Impact of runoff on superficial femoral artery endoluminal interventions for rest pain and tissue loss. J Vasc Surg. 2008;48:619\u201325. https:\/\/doi.org\/10.1016\/j.jvs.2008.04.013. discussion 625.","journal-title":"J Vasc Surg"},{"key":"1255_CR21","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","volume":"42","author":"J Escaned","year":"2021","unstructured":"Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021;42:4624\u201334. https:\/\/doi.org\/10.1093\/eurheartj\/ehab702.","journal-title":"Eur Heart J"},{"key":"1255_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.121.056680","volume":"144","author":"PC Smits","year":"2021","unstructured":"Smits PC, Frigoli E, Tijssen J, J\u00fcni P, Vranckx P, Ozaki Y, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial. Circulation. 2021;144:1196\u2013211. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056680.","journal-title":"Circulation"},{"key":"1255_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.hrthm.2024.01.025","volume":"21","author":"WS Ciou","year":"2024","unstructured":"Ciou WS, Wang CC, Lin FJ, Chao TF, Lin SY. Comparison of different direct oral anticoagulant regimens in atrial fibrillation patients with high bleeding risk. Heart Rhythm. 2024;21:715\u201322. https:\/\/doi.org\/10.1016\/j.hrthm.2024.01.025.","journal-title":"Heart Rhythm"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01255-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-026-01255-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01255-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:04:36Z","timestamp":1781809476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-026-01255-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1255"],"URL":"https:\/\/doi.org\/10.1007\/s12928-026-01255-5","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O. Iida received remuneration from Boston Scientific Japan, W. L. Gore & Associates G.K., BD, and TERUMO. T. Ishihara received lecture fees from Nipro and Kaneka. T. Mano received a research grant from Abbott Vascular Japan. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The current study was an observational investigation without intervention or invasiveness and did not involve human biological specimens. Therefore, in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan, written informed consent from patients was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}